CLINICAL PHASE I-II STUDY OF CIS-DICHLORODIAMMINEPLATINUM(II) GIVEN BY CONTINUOUS IV INFUSION

Abstract

To determine the efficacy and toxicity of cis-dichlorodiammineplatinum(II) and (DDP) by a continuous i.v. infusion (CIVI) schedule, 34 patients with a variety of solid tumors were studied. All patients were refractory to prior chemotherapy and received a loading dose of 5 mg/m2 of DDP i.v. followed by 20 mg/m2 by CIVI daily for 5 days. In 25 evaluable patients, there were 4 (16%) complete or partial responders, 9 (25%) with stable disease, and 12 (48%) with tumor progression. One complete and 1 partial remission were seen in 2 patients with disseminated basal cell carcinoma, with partial responses also seen in cervical and head and neck squamous cancer. Patients experienced renal damage (21%) and audiotoxicity (10%). Nausea and vomiting was severe in only 6%. DDP by CIVI appears to have comparable toxicity to DDP administered by other schedules; however, the diminished gastrointestinal toxicity makes the drug better tolerated by patients for whom the inconvenience of a 5-day hospitalization was less than that caused by the nausea and vomiting of rapid infusion programs.